Abstract

The Career Development Program is a critical component of the SPORE in Prostate Cancer, as it provides a mechanism to mentor junior investigators interested in careers in prostate cancer research. The Career Development Program (CDP) uses several mechanisms to recruit these investigators including emails, letters to department chairs and web site announcements. In addition, the Directors of the Robert H. Lurie Comprehensive Cancer Center and the University of Chicago Comprehensive Cancer Center will advertise the CDP when recruiting junior investigators to their respective Institutions. CDP investigators are selected after careful review of their credentials, their proposed projects and their potential to develop an independent career in prostate cancer research. Career Development investigators are clinicians or basic scientists from biomedical science departments at Northwestern University, University of Chicago and NorthShore University HealthSystem. The fact that the awardees come from a variety of departments provides a source of diversity and scientific expertise to members of the SPORE Program. The Career Development Program has a consistent and highly structured process for selection of awardees and a good tracking system for monitoring their progress.
The specific aims of the Career Development Program are:
Specific Aim 1 To recruit and solicit applications for career development investigators through a highly structured process including mechanisms to attract women and minority candidates.
Specific Aim 2 To select, monitor and evaluate career development investigators based on the proposed project, progress reports, publications and attendance at seminars and symposia.
Specific Aim 3 To foster the careers of these junior investigators through a structured program of mentor meetings, conferences, seminars and symposia.

Public Health Relevance

CAREER DEVELOPMENT PROGRAM: PROJECT NARRATIVE The Career Development Program is a critical component of the SPORE in Prostate Cancer, in that it ensures that there will be a continuous influx of talented investigators devoted to prostate cancer research.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA180995-05
Application #
9752251
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2019-08-01
Budget End
2020-07-31
Support Year
5
Fiscal Year
2019
Total Cost
Indirect Cost

  Institution

Name
Northwestern University at Chicago
Department
Type
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611

  Publications

Szmulewitz, Russell Z; Peer, Cody J; Ibraheem, Abiola et al. (2018) Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol 36:1389-1395
Fong, Ka-Wing; Zhao, Jonathan C; Song, Bing et al. (2018) TRIM28 protects TRIM24 from SPOP-mediated degradation and promotes prostate cancer progression. Nat Commun 9:5007
Giri, Veda N; Knudsen, Karen E; Kelly, William K et al. (2018) Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol 36:414-424
Anker, Jonathan F; Mok, Hanlin; Naseem, Anum F et al. (2018) A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer. J Vis Exp :
Hussain, Maha; Daignault-Newton, Stephanie; Twardowski, Przemyslaw W et al. (2018) Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol 36:991-999
Pascal, Laura E; Wang, Yao; Zhong, Mingming et al. (2018) EAF2 and p53 Co-Regulate STAT3 Activation in Prostate Cancer. Neoplasia 20:351-363
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Anker, Jonathan F; Naseem, Anum F; Mok, Hanlin et al. (2018) Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy. Nat Commun 9:1591
Zang, Yachen; Pascal, Laura E; Zhou, Yibin et al. (2018) ELL2 regulates DNA non-homologous end joining (NHEJ) repair in prostate cancer cells. Cancer Lett 415:198-207
Bhanvadia, Raj R; VanOpstall, Calvin; Brechka, Hannah et al. (2018) MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res 24:3668-3680

Showing the most recent 10 out of 67 publications